NCT lookup

Inclusion Criteria:

* Patients aged ≥ 18 years old

  -. Signed ICF, including patient's consent for genetic testing specimens from primary tumor and blood samples
* Early HER2-negative BC (stages 2 and 3)
* Compliance with at least 1 of the criteria for BRCA1/2 testing in accordance with the clinical guidelines of the Ministry of Health of the Russian Federation
* Unknown BRCAm status or negative BRCAm PCR test
* Performed surgical treatment (not more than 7 months before inclusion)

  -. High risk of recurrence according to one or more criteria:
  1. incomplete pathomorphological response (in case of neoadjuvant therapy)
  2. CPS-EG 3 scale score 3 and more (in case of neoadjuvant therapy)
  3. presence of ≥ 4 metastatic lymph nodes in HR+ pts (in case of only adjuvant therapy)
  4. ≥pT2 or ≥pN1 in TNBC pts (in case of only adjuvant therapy)
  5. Any other high risk criterion according to investigators opinion
* The presence of postoperative or biopsy FFPE

Exclusion Criteria:

* Participation in another clinical study with an investigational product during the last 3 months
* Confirmation that the subject was already included in this study before
* Absence of a written informed consent form; Data erroneously collected from subjects for which written consent is not available, will not be included in or will be deleted from the study database

• Arkhangelsk, Russia
• Barnaul, Russia
• Belgorod, Russia
• Chelyabinsk, Russia
• Grozny, Russia
• Irkutsk, Russia
• Khanty-Mansiysk, Russia
• Krasnodar, Russia
• Krasnoyarsk, Russia
• Moscow, Russia
• Nal'chik, Russia
• Nyzhny Novgorod, Russia
• Ryazan, Russia
• Saint Petersburg, Russia
• Severodvinsk, Russia
• Sochi, Russia
• Ufa, Russia
• Vladivostok, Russia
• Yaroslavl, Russia